NCT02260804View on ClinicalTrials.gov

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

January 4, 2018

Study Completion Date

September 4, 2019

Conditions
Follicular Lymphoma
Interventions
BIOLOGICAL

CT-P10

375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.

BIOLOGICAL

Rituxan

375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY